Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9189739,half-life,"For normal rabbits we obtained a half-life of 15.8 hours (method I) and 17.5 +/- 1.0 hours (mean +/- SEM, method II), respectively.",Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9189739/),h,15.8,2730,DB08818,Hyaluronan
,9189739,half-life,"For normal rabbits we obtained a half-life of 15.8 hours (method I) and 17.5 +/- 1.0 hours (mean +/- SEM, method II), respectively.",Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9189739/),h,17.5,2731,DB08818,Hyaluronan
,9189739,half-life,"Four weeks after injury, during the developing phase of osteoarthritis, the half-life of hyaluronan rose significantly to 23.5 +/- 2.1 hours and returned to normal levels (17.4 +/- 2.7 hours) 12 weeks after the operation (osteoarthritis developed).",Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9189739/),h,23.5,2732,DB08818,Hyaluronan
,9189739,half-life,"Four weeks after injury, during the developing phase of osteoarthritis, the half-life of hyaluronan rose significantly to 23.5 +/- 2.1 hours and returned to normal levels (17.4 +/- 2.7 hours) 12 weeks after the operation (osteoarthritis developed).",Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9189739/),h,17.4,2733,DB08818,Hyaluronan
,30080939,plasma concentration,"The MP plasma concentration at 6 days for injection for the entire group (mean ± standard deviation [s.d.], pg/mL) was 96 ± 104.",Variability in plasma concentrations of methylprednisolone 6 days after intrasynovial injection of methylprednisolone acetate in racing horses: A field study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080939/),,96,6730,DB08818,Hyaluronan
,31389248,EE,The obtained HA@Tri-BLs possessed a PS of 118.5 nm around with an EE of 99.56%.,Hyaluronic acid-functionalized bilosomes for targeted delivery of tripterine to inflamed area with enhancive therapy on arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31389248/),,99.56,9025,DB08818,Hyaluronan
,31389248,bioavailability,"HA@Tri-BLs exhibited excellent cellular uptake and targeted delivery efficiency for Tri, which resulted in elongation of circulatory residence time and enhancement of intra-arthritic bioavailability (799.9% relative to Tri solution).",Hyaluronic acid-functionalized bilosomes for targeted delivery of tripterine to inflamed area with enhancive therapy on arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31389248/),%,799.9,9026,DB08818,Hyaluronan
,19060478,progression-free survival,"Median survival was 16.6 months, while median progression-free survival was 6.2 months.",A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19060478/),month,6.2,9310,DB08818,Hyaluronan
,14506195,MTD,"The MTD was established at 50 mCi/m(2), at which level dose-limiting myelotoxicity was seen in one of six patients.",Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506195/),mc,50,9548,DB08818,Hyaluronan
,14506195,absorbed dose,The absorbed dose in red marrow was 1.82 +/- 0.11 cGy/mCi for males and 2.35 +/- 0.10 for females.,Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506195/),[cgy] / [mci],1.82,9549,DB08818,Hyaluronan
,14506195,absorbed dose,The absorbed dose in red marrow was 1.82 +/- 0.11 cGy/mCi for males and 2.35 +/- 0.10 for females.,Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506195/),[cgy] / [mci],2.35,9550,DB08818,Hyaluronan
,14506195,MTD,The MTD was established at 50 mCi/m(2).,Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506195/),[mci] / [m(2],50,9551,DB08818,Hyaluronan
,18675905,bioavailability,"Following intratracheal spray of the scutellarin solution, the bioavailability was found to be approximately 77% in rats, which was >30-fold higher than that via the peroral route.",Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675905/),%,77,9788,DB08818,Hyaluronan
,18675905,absolute bioavailability,"Incorporating mucoadhesive polymeric mixtures into the scutellarin particles, the MTR decreased by sixfold, and the absolute bioavailability of the drug was found to increase from 70.1% to 97.9% despite a decrease in the FPF.",Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675905/),%,70.1,9789,DB08818,Hyaluronan
,18675905,absolute bioavailability,"Incorporating mucoadhesive polymeric mixtures into the scutellarin particles, the MTR decreased by sixfold, and the absolute bioavailability of the drug was found to increase from 70.1% to 97.9% despite a decrease in the FPF.",Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675905/),%,97.9,9790,DB08818,Hyaluronan
,12102643,elimination half-lives,"Elimination of (131)I-labelled NASHA from the knee was characterised by a fast initial phase and a slow late phase, and conformed to a three-exponential-function model with elimination half-lives of 1.5 hours, 1.5 days and 4 weeks.",Elimination of stabilised hyaluronan from the knee joint in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102643/),h,1.5,9954,DB08818,Hyaluronan
,12102643,elimination half-lives,"Elimination of (131)I-labelled NASHA from the knee was characterised by a fast initial phase and a slow late phase, and conformed to a three-exponential-function model with elimination half-lives of 1.5 hours, 1.5 days and 4 weeks.",Elimination of stabilised hyaluronan from the knee joint in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102643/),d,1.5,9955,DB08818,Hyaluronan
,12102643,elimination half-lives,"Elimination of (131)I-labelled NASHA from the knee was characterised by a fast initial phase and a slow late phase, and conformed to a three-exponential-function model with elimination half-lives of 1.5 hours, 1.5 days and 4 weeks.",Elimination of stabilised hyaluronan from the knee joint in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102643/),weeks,4,9956,DB08818,Hyaluronan
,12102643,half-times,"The elimination kinetics of (131)I-labelled NASHA from the human knee joint were described by three distinct phases, with half-times of 1.5 hours, 1.5 days and 4 weeks.",Elimination of stabilised hyaluronan from the knee joint in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102643/),h,1.5,9957,DB08818,Hyaluronan
,12102643,half-times,"The elimination kinetics of (131)I-labelled NASHA from the human knee joint were described by three distinct phases, with half-times of 1.5 hours, 1.5 days and 4 weeks.",Elimination of stabilised hyaluronan from the knee joint in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102643/),d,1.5,9958,DB08818,Hyaluronan
,12102643,half-times,"The elimination kinetics of (131)I-labelled NASHA from the human knee joint were described by three distinct phases, with half-times of 1.5 hours, 1.5 days and 4 weeks.",Elimination of stabilised hyaluronan from the knee joint in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102643/),weeks,4,9959,DB08818,Hyaluronan
,28027947,IC50,DTX-HPLGA displayed a low IC50 of 0.91μg/mL in CD44+ A549 cells and a prolonged elimination half-life of 4.13h in nude mice.,Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28027947/),[μg] / [ml],0.91,15262,DB08818,Hyaluronan
,28027947,elimination half-life,DTX-HPLGA displayed a low IC50 of 0.91μg/mL in CD44+ A549 cells and a prolonged elimination half-life of 4.13h in nude mice.,Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28027947/),h,4.13,15263,DB08818,Hyaluronan
,33278965,encapsulation efficiency,"Chondroitin sulfate-hybridized zein nanoparticles (zein/CS NPs) were developed for targeted delivery of docetaxel, which exhibited mean diameters of 157.8 ± 3.6 nm and docetaxel encapsulation efficiency of 64.2 ± 1.9 %.",Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33278965/),%,64.2,18949,DB08818,Hyaluronan
,22102374,half-life,"The half-life of the fluid component, a high-molecular weight hylan, was 1.5 ± 0.2 days while the half-life of the hylan gel component, a crosslinked hylan, was 8.8 ± 0.9 days.",Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102374/),d,1.5,22144,DB08818,Hyaluronan
,22102374,half-life,"The half-life of the fluid component, a high-molecular weight hylan, was 1.5 ± 0.2 days while the half-life of the hylan gel component, a crosslinked hylan, was 8.8 ± 0.9 days.",Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102374/),d,8.8,22145,DB08818,Hyaluronan
,31330211,zeta potential,The average size of spherical PTX-NHOA micelles was 162.7 nm with a zeta potential of -27.6 mv.,The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),mv,-,22319,DB08818,Hyaluronan
,31330211,zeta potential,The average size of spherical PTX-NHOA micelles was 162.7 nm with a zeta potential of -27.6 mv.,The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),mv,27.6,22320,DB08818,Hyaluronan
,31330211,encapsulation efficiency (EE),"The encapsulation efficiency (EE) and drug loading (DL) of PTX-NHOA micelles were 92.64% and 6.96%, respectively.",The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),%,92.64,22321,DB08818,Hyaluronan
,31330211,drug loading (DL),"The encapsulation efficiency (EE) and drug loading (DL) of PTX-NHOA micelles were 92.64% and 6.96%, respectively.",The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),%,6.96,22322,DB08818,Hyaluronan
,21545233,lengths,The mean lengths of DMs were 496.6 ± 2.9 μm for h-DM and 494.5 ± 1.3 μm for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),μm,496.6,33612,DB08818,Hyaluronan
,21545233,lengths,The mean lengths of DMs were 496.6 ± 2.9 μm for h-DM and 494.5 ± 1.3 μm for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),μm,494.5,33613,DB08818,Hyaluronan
,21545233,maximum plasma ST concentrations,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[ng] / [ml],44.6,33614,DB08818,Hyaluronan
,21545233,maximum plasma ST concentrations,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[ng] / [ml],38.4,33615,DB08818,Hyaluronan
,21545233,Cmax,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[h·ng] / [ml],24.6,33616,DB08818,Hyaluronan
,21545233,Cmax,"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[ng] / [ml],38.4,33617,DB08818,Hyaluronan
,21545233,areas under the plasma ST concentration versus time curves (AUC),"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[h·ng] / [ml],24.6,33618,DB08818,Hyaluronan
,21545233,areas under the plasma ST concentration versus time curves (AUC),"The maximum plasma ST concentrations, Cmax, and the areas under the plasma ST concentration versus time curves (AUC) were 44.6 ± 4.9 ng/ml and 24.6 ± 3.9 ng · h/ml for h-DM and 38.4 ± 2.7 ng/ml and 14.1 ± 1.5 ng · h/ml for d-DM.",Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),[h·ng] / [ml],14.1,33619,DB08818,Hyaluronan
,21545233,bioavailabilities,The bioavailabilities of ST from DMs were calculated as 100.7 ± 18.8% for h-DM and 93.6 ± 10.2% for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),%,100.7,33620,DB08818,Hyaluronan
,21545233,bioavailabilities,The bioavailabilities of ST from DMs were calculated as 100.7 ± 18.8% for h-DM and 93.6 ± 10.2% for d-DM.,Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545233/),%,93.6,33621,DB08818,Hyaluronan
,20649573,IC(50),"In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors.","A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649573/),nM,17,34167,DB08818,Hyaluronan
,20649573,IC(50),"In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors.","A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649573/),nM,181,34168,DB08818,Hyaluronan
,9380343,half-lives,"Kinetic studies showed that the half-lives of FITC-collagen, FL-HA, and the mixed substance were 5.70, 2.09, and 8.41 days, respectively.",Evaluation of collagen gel and hyaluronic acid as vitreous substitutes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9380343/),d,5.70,36528,DB08818,Hyaluronan
,9380343,half-lives,"Kinetic studies showed that the half-lives of FITC-collagen, FL-HA, and the mixed substance were 5.70, 2.09, and 8.41 days, respectively.",Evaluation of collagen gel and hyaluronic acid as vitreous substitutes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9380343/),d,2.09,36529,DB08818,Hyaluronan
,9380343,half-lives,"Kinetic studies showed that the half-lives of FITC-collagen, FL-HA, and the mixed substance were 5.70, 2.09, and 8.41 days, respectively.",Evaluation of collagen gel and hyaluronic acid as vitreous substitutes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9380343/),d,8.41,36530,DB08818,Hyaluronan
,33250343,Serum peak concentrations (cmax),"Serum peak concentrations (cmax) of gemcitabine were low at 5.5 µg/ml compared to the 10 to 30 µg/ml levels observed after a single intravenous dose of 1,000 mg/m2 gemcitabine.",A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33250343/),[μg] / [ml],5.5,43146,DB08818,Hyaluronan
,33250343,Serum peak concentrations (cmax),"Serum peak concentrations (cmax) of gemcitabine were low at 5.5 µg/ml compared to the 10 to 30 µg/ml levels observed after a single intravenous dose of 1,000 mg/m2 gemcitabine.",A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33250343/),[μg] / [ml],10 to 30,43147,DB08818,Hyaluronan
,22142621,K(m),"I.v. administration of flHA revealed non-linear Michaelis-Menten pharmacokinetics compatible with a saturable, receptor-mediated clearance system (K(m)=11.6μg/ml±46.0%, V(max)=1.69μg/ml/min±59.7%).",A comprehensive model of hyaluronan turnover in the mouse. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22142621/),[μg] / [ml],11.6,43579,DB08818,Hyaluronan
,22142621,V(max),"I.v. administration of flHA revealed non-linear Michaelis-Menten pharmacokinetics compatible with a saturable, receptor-mediated clearance system (K(m)=11.6μg/ml±46.0%, V(max)=1.69μg/ml/min±59.7%).",A comprehensive model of hyaluronan turnover in the mouse. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22142621/),[μg] / [min·ml],1.69,43580,DB08818,Hyaluronan
,29486258,EE,"The EE of MTO-mPEG-PENPs and MTO-PENPs were 99.02% and 98.33%, respectively.",Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),%,99.02,48984,DB08818,Hyaluronan
,29486258,EE,"The EE of MTO-mPEG-PENPs and MTO-PENPs were 99.02% and 98.33%, respectively.",Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),%,98.33,48985,DB08818,Hyaluronan
,29486258,MRT,The MRT of MTO increased from 117.83min (MTO solutions) and 162.34min (MTO-PENPs) to 344.42min (MTO-mPEG-PENPs).,Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),min,117.83,48986,DB08818,Hyaluronan
,29486258,MRT,The MRT of MTO increased from 117.83min (MTO solutions) and 162.34min (MTO-PENPs) to 344.42min (MTO-mPEG-PENPs).,Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),min,162.34,48987,DB08818,Hyaluronan
,29486258,MRT,The MRT of MTO increased from 117.83min (MTO solutions) and 162.34min (MTO-PENPs) to 344.42min (MTO-mPEG-PENPs).,Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),min,344.42,48988,DB08818,Hyaluronan
,27468491,Zeta potential,"The self-prepared AHHPs had an average particle size of (367.43 ± 2.72) nm, Zeta potential of (-15. 70 ± 1.25) mV, and average entrapment efficiency of (66.03 ± 3.81)%.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),mv,-,51515,DB08818,Hyaluronan
,27468491,Zeta potential,"The self-prepared AHHPs had an average particle size of (367.43 ± 2.72) nm, Zeta potential of (-15. 70 ± 1.25) mV, and average entrapment efficiency of (66.03 ± 3.81)%.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),mv,15. 70,51516,DB08818,Hyaluronan
,27468491,entrapment efficiency,"The self-prepared AHHPs had an average particle size of (367.43 ± 2.72) nm, Zeta potential of (-15. 70 ± 1.25) mV, and average entrapment efficiency of (66.03 ± 3.81)%.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),%,66.03,51517,DB08818,Hyaluronan
,27468491,area under concentration-time Curve (AUC)(0-48 h),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),[u] / [h·ml],162.06,51518,DB08818,Hyaluronan
,27468491,area under concentration-time Curve (AUC)(0-48 h),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),[u] / [h·ml],46.38,51519,DB08818,Hyaluronan
,27468491,AUC(0-∞),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),[u] / [h·ml],203.74,51520,DB08818,Hyaluronan
,27468491,AUC(0-∞),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),[u] / [h·ml],51.44,51521,DB08818,Hyaluronan
,27468491,mean residence time (MRT) (0-72h),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),h,4.35,51522,DB08818,Hyaluronan
,27468491,mean residence time (MRT) (0-72h),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),h,1.76,51523,DB08818,Hyaluronan
,27468491,MRT(0-∞),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),h,7.53,51524,DB08818,Hyaluronan
,27468491,MRT(0-∞),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),h,2.44,51525,DB08818,Hyaluronan
,27468491,peak concentration (Cmax),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),[u] / [ml],30.37,51526,DB08818,Hyaluronan
,27468491,peak concentration (Cmax),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),[u] / [ml],26.06,51527,DB08818,Hyaluronan
,27468491,time to peak concentration (Tmax),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),h,0.75,51528,DB08818,Hyaluronan
,27468491,time to peak concentration (Tmax),"The intravenous injection of AHHPs and free AAS produced an area under concentration-time Curve (AUC)(0-48 h) of (162.06 ± 4.01) U/mL · h and (46.38 ± 1.98) U/mL · h, AUC(0-∞) of (203.74 ± 12.91) U/mL · h and (51.44 ± 3.01) U/mL · h, mean residence time (MRT) (0-72h) of (4.35 ± 0.06) h and (1.76 ± 0.06) h, MRT(0-∞) of (7.53 ± 1.05) h and (2.44 ± 0.29) h, peak concentration (Cmax) of (30.37 ± 0.43) U/mL and (26.06 ± 0.88) U/mL, and time to peak concentration (Tmax) of (0.75 ± 0.00) h and (0.08 ± 0.00) h, respectively.",[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468491/),h,0.08,51529,DB08818,Hyaluronan
,31532629,elimination half-life,"Interestingly, DTX-CMHN displayed a long elimination half-life of 5.75 h, in contrast to half-lives of 2.11 and 0.75 h for its non-cross-linked counterpart (DTX-MHN) and free DTX, respectively.",CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31532629/),h,5.75,52423,DB08818,Hyaluronan
,31532629,half-lives,"Interestingly, DTX-CMHN displayed a long elimination half-life of 5.75 h, in contrast to half-lives of 2.11 and 0.75 h for its non-cross-linked counterpart (DTX-MHN) and free DTX, respectively.",CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31532629/),h,2.11,52424,DB08818,Hyaluronan
,31532629,half-lives,"Interestingly, DTX-CMHN displayed a long elimination half-life of 5.75 h, in contrast to half-lives of 2.11 and 0.75 h for its non-cross-linked counterpart (DTX-MHN) and free DTX, respectively.",CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31532629/),h,0.75,52425,DB08818,Hyaluronan
,28835099,IC50,HA-GS-MP exhibited obvious targetability and markedly enhanced antitumor effect to OCI/AML-2 human AML cells (IC50 = 16.9 μg 6-MP equiv./mL).,Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28835099/),μg,16.9,53138,DB08818,Hyaluronan
,28835099,elimination half-life,The pharmacokinetic studies displayed that Cy5-labeled HA-GS-MP had a long circulation time in mice (elimination half-life = 4.37 h).,Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28835099/),h,4.37,53139,DB08818,Hyaluronan
,15814135,T(max),"Non-volatile radioactivity slowly appeared in plasma, with a median T(max) of 12 h, and then declined with a mean half-life of 69 h.","Pharmacokinetic behaviour of ACP gel, an autocrosslinked hyaluronan derivative, after intraperitoneal administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814135/),h,12,53690,DB08818,Hyaluronan
,15814135,half-life,"Non-volatile radioactivity slowly appeared in plasma, with a median T(max) of 12 h, and then declined with a mean half-life of 69 h.","Pharmacokinetic behaviour of ACP gel, an autocrosslinked hyaluronan derivative, after intraperitoneal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814135/),h,69,53691,DB08818,Hyaluronan
,15359571,Mon,"Monomeric content of hGH recovered from SR-hGH was 97.4% by SEC analysis, and its purity was 96% by RP-HPLC analysis.",Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),%,97.4,55510,DB08818,Hyaluronan
,15359571,Cmax,Delayed absorption of hGH was observed with Cmax of 69.5+/-8.0 ng/ml and Tmax between 10 and 12 h.,Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),[ng] / [ml],69.5,55511,DB08818,Hyaluronan
,15359571,Tmax,Delayed absorption of hGH was observed with Cmax of 69.5+/-8.0 ng/ml and Tmax between 10 and 12 h.,Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),h,10 and 12,55512,DB08818,Hyaluronan
,18538437,Recovery,"Recovery of lactose blends of HMO from stage II of the twin-stage impinger (TSI) reached 43%, indicating favorable delivery of the drug to the lung via inhalation.",Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538437/),%,43,56815,DB08818,Hyaluronan
,21524115,blood elimination half-life,"For hyaluronic acid (HA) outer layers, a long blood elimination half-life (∼9 h) and low accumulation (∼10-15% recovered fluorescence/g) in the liver were observed, illustrating that these systems can be designed to be highly appropriate for clinical translation.",Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21524115/),h,∼9,62155,DB08818,Hyaluronan
,14627130,t1/2,"A mean t1/2 in plasma of 54.8 +/- 11.5 h, 76.1 +/- 21.8 h, and 68.5 +/- 21.2 h was found for the 25-, 50-, and 100-mg dose group, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),h,54.8,67257,DB08818,Hyaluronan
,14627130,t1/2,"A mean t1/2 in plasma of 54.8 +/- 11.5 h, 76.1 +/- 21.8 h, and 68.5 +/- 21.2 h was found for the 25-, 50-, and 100-mg dose group, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),h,76.1,67258,DB08818,Hyaluronan
,14627130,t1/2,"A mean t1/2 in plasma of 54.8 +/- 11.5 h, 76.1 +/- 21.8 h, and 68.5 +/- 21.2 h was found for the 25-, 50-, and 100-mg dose group, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),h,68.5,67259,DB08818,Hyaluronan
,14627130,Tumor uptake,"Tumor uptake was 12.9 +/- 5.9, 26.2 +/- 3.1, and 15.4 +/- 1.9% of the injected dose (ID)/kg for the 25-, 50-, and 100-mg dose group, respectively, while the tumor to bone marrow ratios for these groups were 1.7 +/- 0.5, 3.2 +/- 1.1, and 2.0 +/- 0.6, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),%,12.9,67260,DB08818,Hyaluronan
,14627130,Tumor uptake,"Tumor uptake was 12.9 +/- 5.9, 26.2 +/- 3.1, and 15.4 +/- 1.9% of the injected dose (ID)/kg for the 25-, 50-, and 100-mg dose group, respectively, while the tumor to bone marrow ratios for these groups were 1.7 +/- 0.5, 3.2 +/- 1.1, and 2.0 +/- 0.6, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),%,26.2,67261,DB08818,Hyaluronan
,14627130,Tumor uptake,"Tumor uptake was 12.9 +/- 5.9, 26.2 +/- 3.1, and 15.4 +/- 1.9% of the injected dose (ID)/kg for the 25-, 50-, and 100-mg dose group, respectively, while the tumor to bone marrow ratios for these groups were 1.7 +/- 0.5, 3.2 +/- 1.1, and 2.0 +/- 0.6, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),%,15.4,67262,DB08818,Hyaluronan
,14627130,tumor to bone marrow ratios,"Tumor uptake was 12.9 +/- 5.9, 26.2 +/- 3.1, and 15.4 +/- 1.9% of the injected dose (ID)/kg for the 25-, 50-, and 100-mg dose group, respectively, while the tumor to bone marrow ratios for these groups were 1.7 +/- 0.5, 3.2 +/- 1.1, and 2.0 +/- 0.6, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),,1.7,67263,DB08818,Hyaluronan
,14627130,tumor to bone marrow ratios,"Tumor uptake was 12.9 +/- 5.9, 26.2 +/- 3.1, and 15.4 +/- 1.9% of the injected dose (ID)/kg for the 25-, 50-, and 100-mg dose group, respectively, while the tumor to bone marrow ratios for these groups were 1.7 +/- 0.5, 3.2 +/- 1.1, and 2.0 +/- 0.6, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),,3.2,67264,DB08818,Hyaluronan
,14627130,tumor to bone marrow ratios,"Tumor uptake was 12.9 +/- 5.9, 26.2 +/- 3.1, and 15.4 +/- 1.9% of the injected dose (ID)/kg for the 25-, 50-, and 100-mg dose group, respectively, while the tumor to bone marrow ratios for these groups were 1.7 +/- 0.5, 3.2 +/- 1.1, and 2.0 +/- 0.6, respectively.","Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14627130/),,2.0,67265,DB08818,Hyaluronan
,32113915,IC50,"The IC50 was reduced by a factor of two in HT-29 cells (IC50 39 µM vs 74 µM, respectively), and resulted almost 1.3 fold lower in B6KPC3 cells (18 µM vs 23 µM respectively).",Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),μM,39,68215,DB08818,Hyaluronan
,32113915,IC50,"The IC50 was reduced by a factor of two in HT-29 cells (IC50 39 µM vs 74 µM, respectively), and resulted almost 1.3 fold lower in B6KPC3 cells (18 µM vs 23 µM respectively).",Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),μM,74,68216,DB08818,Hyaluronan
,32113915,IC50,"The IC50 was reduced by a factor of two in HT-29 cells (IC50 39 µM vs 74 µM, respectively), and resulted almost 1.3 fold lower in B6KPC3 cells (18 µM vs 23 µM respectively).",Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),μM,18,68217,DB08818,Hyaluronan
,32113915,IC50,"The IC50 was reduced by a factor of two in HT-29 cells (IC50 39 µM vs 74 µM, respectively), and resulted almost 1.3 fold lower in B6KPC3 cells (18 µM vs 23 µM respectively).",Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),μM,23,68218,DB08818,Hyaluronan
,32113915,IC50,Whereas toxic effects of both drug and DACHPt-loaded nanoparticles were comparable in the A549 cell line (IC50 11 µM vs 12 µM).,Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),μM,11,68219,DB08818,Hyaluronan
,32113915,IC50,Whereas toxic effects of both drug and DACHPt-loaded nanoparticles were comparable in the A549 cell line (IC50 11 µM vs 12 µM).,Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),μM,12,68220,DB08818,Hyaluronan
,32113915,AUC,An AUC six times higher (24 h * mg/L) than the value obtained following the administration of oxaliplatin solution (3.76 h * mg/L) was found.,Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),[h·mg] / [l],24,68221,DB08818,Hyaluronan
,32113915,AUC,An AUC six times higher (24 h * mg/L) than the value obtained following the administration of oxaliplatin solution (3.76 h * mg/L) was found.,Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),[h·mg] / [l],3.76,68222,DB08818,Hyaluronan
,32113915,Cmax,Cmax was almost five times higher than the control (11.4 mg/L for NP vs 2.48 mg/L).,Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),[mg] / [l],11.4,68223,DB08818,Hyaluronan
,32113915,Cmax,Cmax was almost five times higher than the control (11.4 mg/L for NP vs 2.48 mg/L).,Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32113915/),[mg] / [l],2.48,68224,DB08818,Hyaluronan
,23176425,area under the curve,"Mean ± SD area under the curve, peak concentration, and terminal half-life for unbound (plasma) and total (serum) platinum were 774.6 ± 221.1 ng•h/mL and 3,562.1 ± 2,031.1 ng•h/mL, 56.5 ± 20.9 ng/mL and 81.6 ± 40.4 ng/mL, and 33.6 ± 16.1 hours and 51.2 ± 29.1 hours, respectively.",Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176425/),[h·ng] / [ml],774.6,71300,DB08818,Hyaluronan
,23176425,peak concentration,"Mean ± SD area under the curve, peak concentration, and terminal half-life for unbound (plasma) and total (serum) platinum were 774.6 ± 221.1 ng•h/mL and 3,562.1 ± 2,031.1 ng•h/mL, 56.5 ± 20.9 ng/mL and 81.6 ± 40.4 ng/mL, and 33.6 ± 16.1 hours and 51.2 ± 29.1 hours, respectively.",Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176425/),[h·ng] / [ml],"3,562.1",71301,DB08818,Hyaluronan
,23176425,peak concentration,"Mean ± SD area under the curve, peak concentration, and terminal half-life for unbound (plasma) and total (serum) platinum were 774.6 ± 221.1 ng•h/mL and 3,562.1 ± 2,031.1 ng•h/mL, 56.5 ± 20.9 ng/mL and 81.6 ± 40.4 ng/mL, and 33.6 ± 16.1 hours and 51.2 ± 29.1 hours, respectively.",Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176425/),[ng] / [ml],56.5,71302,DB08818,Hyaluronan
,23176425,peak concentration,"Mean ± SD area under the curve, peak concentration, and terminal half-life for unbound (plasma) and total (serum) platinum were 774.6 ± 221.1 ng•h/mL and 3,562.1 ± 2,031.1 ng•h/mL, 56.5 ± 20.9 ng/mL and 81.6 ± 40.4 ng/mL, and 33.6 ± 16.1 hours and 51.2 ± 29.1 hours, respectively.",Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176425/),h,33.6,71303,DB08818,Hyaluronan
,23176425,terminal half-life,"Mean ± SD area under the curve, peak concentration, and terminal half-life for unbound (plasma) and total (serum) platinum were 774.6 ± 221.1 ng•h/mL and 3,562.1 ± 2,031.1 ng•h/mL, 56.5 ± 20.9 ng/mL and 81.6 ± 40.4 ng/mL, and 33.6 ± 16.1 hours and 51.2 ± 29.1 hours, respectively.",Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176425/),h,51.2,71304,DB08818,Hyaluronan
,19538672,SFAC,"In vitro study: After AI-FeHAI placement, SFAC was highest (140.78+63.81 microg/mL) at first sampling time.",In vitro and in vivo evaluation of ferric-hyaluronate implants for delivery of amikacin sulfate to the tarsocrural joint of horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19538672/),[μg] / [ml],140.78,73526,DB08818,Hyaluronan
<,19538672,SFAC,By 24 hours SFAC was <16 microg/mL.,In vitro and in vivo evaluation of ferric-hyaluronate implants for delivery of amikacin sulfate to the tarsocrural joint of horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19538672/),[μg] / [ml],16,73527,DB08818,Hyaluronan
,19538672,SFAC,"After intra-articular injection, SFAC was the highest (377.91 +/- 40.15 microg/mL) at first sampling time.",In vitro and in vivo evaluation of ferric-hyaluronate implants for delivery of amikacin sulfate to the tarsocrural joint of horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19538672/),[μg] / [ml],377.91,73528,DB08818,Hyaluronan
<,19538672,SFAC,By 48 hours SFAC was <16 microg/mL.,In vitro and in vivo evaluation of ferric-hyaluronate implants for delivery of amikacin sulfate to the tarsocrural joint of horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19538672/),[μg] / [ml],16,73529,DB08818,Hyaluronan
,24465870,bioavailability,"The bioavailability of the exenatide-loaded microspheres, relative to subcutaneous injection of exenatide, reached 10.2%.",Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465870/),%,10.2,74023,DB08818,Hyaluronan
,26806745,zeta potential,AHSP had an average particle size of 413.80∓10.97 nm with a zeta potential of -20.37∓2.38 mV.,[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),mv,-,78301,DB08818,Hyaluronan
,26806745,zeta potential,AHSP had an average particle size of 413.80∓10.97 nm with a zeta potential of -20.37∓2.38 mV.,[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),mv,20.37∓2.38,78302,DB08818,Hyaluronan
,26806745,AUC(0-48 h),"The AUC(0-48 h) of AHSP and free asparaginase was 137.34∓1.82 U/mL and 46.38 ∓1.98 U/mL, and their AUC(0-∞) was 164.66∓6.88 U/mL and 51.44∓3.01 U/mL with half-lives of 4.62∓0.60 h and 1.86∓0.38 h, respectively.",[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),[u] / [ml],137.,78303,DB08818,Hyaluronan
,26806745,AUC(0-48 h),"The AUC(0-48 h) of AHSP and free asparaginase was 137.34∓1.82 U/mL and 46.38 ∓1.98 U/mL, and their AUC(0-∞) was 164.66∓6.88 U/mL and 51.44∓3.01 U/mL with half-lives of 4.62∓0.60 h and 1.86∓0.38 h, respectively.",[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),[u] / [ml],46.38,78304,DB08818,Hyaluronan
,26806745,AUC(0-∞),"The AUC(0-48 h) of AHSP and free asparaginase was 137.34∓1.82 U/mL and 46.38 ∓1.98 U/mL, and their AUC(0-∞) was 164.66∓6.88 U/mL and 51.44∓3.01 U/mL with half-lives of 4.62∓0.60 h and 1.86∓0.38 h, respectively.",[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),[u] / [ml],164.,78305,DB08818,Hyaluronan
,26806745,AUC(0-∞),"The AUC(0-48 h) of AHSP and free asparaginase was 137.34∓1.82 U/mL and 46.38 ∓1.98 U/mL, and their AUC(0-∞) was 164.66∓6.88 U/mL and 51.44∓3.01 U/mL with half-lives of 4.62∓0.60 h and 1.86∓0.38 h, respectively.",[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),[u] / [ml],51.,78306,DB08818,Hyaluronan
,26806745,half-lives,"The AUC(0-48 h) of AHSP and free asparaginase was 137.34∓1.82 U/mL and 46.38 ∓1.98 U/mL, and their AUC(0-∞) was 164.66∓6.88 U/mL and 51.44∓3.01 U/mL with half-lives of 4.62∓0.60 h and 1.86∓0.38 h, respectively.",[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),h,4.,78307,DB08818,Hyaluronan
,26806745,half-lives,"The AUC(0-48 h) of AHSP and free asparaginase was 137.34∓1.82 U/mL and 46.38 ∓1.98 U/mL, and their AUC(0-∞) was 164.66∓6.88 U/mL and 51.44∓3.01 U/mL with half-lives of 4.62∓0.60 h and 1.86∓0.38 h, respectively.",[Pharmacokinetics and bioequivalence assessment of a self-assembled asparaginase nanocapsule in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806745/),h,1.,78308,DB08818,Hyaluronan
,1903016,minimal inhibitory concentration,"The minimal inhibitory concentration for gentamicin/SH was 0.5, 0.062 and 2.0 mcg/ml for these pathogens, respectively.",In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903016/),[mcg] / [ml],0.5,80140,DB08818,Hyaluronan
,1903016,minimal inhibitory concentration,"The minimal inhibitory concentration for gentamicin/SH was 0.5, 0.062 and 2.0 mcg/ml for these pathogens, respectively.",In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903016/),[mcg] / [ml],0.062,80141,DB08818,Hyaluronan
,1903016,minimal inhibitory concentration,"The minimal inhibitory concentration for gentamicin/SH was 0.5, 0.062 and 2.0 mcg/ml for these pathogens, respectively.",In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903016/),[mcg] / [ml],2.0,80142,DB08818,Hyaluronan
,1903016,half-life,"The half-life of aqueous gentamicin was 0.9 h, which was shorter than the 2.2 h for SH/gentamicin combination.",In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903016/),h,0.9,80143,DB08818,Hyaluronan
,1903016,half-life,"The half-life of aqueous gentamicin was 0.9 h, which was shorter than the 2.2 h for SH/gentamicin combination.",In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903016/),h,2.2,80144,DB08818,Hyaluronan
,26039249,bioavailability,"The bioavailability of DACHPt/HANP increases by 18.7% and 9.4% during the first 5 and 24 hr, respectively.",A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26039249/),,18,91730,DB08818,Hyaluronan
,26039249,bioavailability,"The bioavailability of DACHPt/HANP increases by 18.7% and 9.4% during the first 5 and 24 hr, respectively.",A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26039249/),%,9.4,91731,DB08818,Hyaluronan
,30006244,polydispersity index,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),,0.39,92330,DB08818,Hyaluronan
,30006244,polydispersity index,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),,0.41,92331,DB08818,Hyaluronan
,30006244,zeta potential,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),mv,13.4,92332,DB08818,Hyaluronan
,30006244,zeta potential,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),mv,11.9,92333,DB08818,Hyaluronan
,30006244,encapsulation efficiency,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),%,23,92334,DB08818,Hyaluronan
,30006244,encapsulation efficiency,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),%,23,92335,DB08818,Hyaluronan
,30006244,Papp,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),[cm] / [s],8.8,92336,DB08818,Hyaluronan
,30006244,Papp,"NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (Papp, 8.8 ± 0.8 vs. 10 ± 1 cm/s).",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),[cm] / [s],10,92337,DB08818,Hyaluronan
,30006244,Tmax,"This directly influenced drug oral bioavailability in rats (Tmax, 1 vs. 2 h; AUC, 1.7 ± 0.3 vs.",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),h,1,92338,DB08818,Hyaluronan
,30006244,Tmax,"This directly influenced drug oral bioavailability in rats (Tmax, 1 vs. 2 h; AUC, 1.7 ± 0.3 vs.",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),h,2,92339,DB08818,Hyaluronan
,30006244,AUC,"This directly influenced drug oral bioavailability in rats (Tmax, 1 vs. 2 h; AUC, 1.7 ± 0.3 vs.",Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30006244/),,1.7,92340,DB08818,Hyaluronan
,27895468,zeta potential,"PRX-loaded NPs consisting of poly(lactic-co-glycolic acid), Eudragit RL, and polyvinyl alcohol were constructed with the following characteristics: particle size of 220 nm, zeta potential of 11.5 mV in phosphate-buffered saline, and loading amount of 4.0% (w/w) of PRX.",Increased localized delivery of piroxicam by cationic nanoparticles after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27895468/),mv,11.5,102578,DB08818,Hyaluronan
,26955748,Area under curve (AUC),"Area under curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and time to reach maximum plasma concentration Tmax), were observed 4398.1±7.90μgh/mL, 145.45±2.25μg/L, 45.74±0.25h, 72±0.50h, respectively of HAC NPs and 119.92±1.78μgh/mL, 46.38±3.42μg/L, 1.2±0.25h, 0.5±0.02h were observed in plain 5-FU solution.",Hyaluronic acid embedded cellulose acetate phthlate core/shell nanoparticulate carrier of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26955748/),[μgh] / [ml],4398.1,109784,DB08818,Hyaluronan
,26955748,time to reach maximum plasma concentration Tmax),"Area under curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and time to reach maximum plasma concentration Tmax), were observed 4398.1±7.90μgh/mL, 145.45±2.25μg/L, 45.74±0.25h, 72±0.50h, respectively of HAC NPs and 119.92±1.78μgh/mL, 46.38±3.42μg/L, 1.2±0.25h, 0.5±0.02h were observed in plain 5-FU solution.",Hyaluronic acid embedded cellulose acetate phthlate core/shell nanoparticulate carrier of 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26955748/),h,72,109785,DB08818,Hyaluronan
,26955748,time to reach maximum plasma concentration Tmax),"Area under curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and time to reach maximum plasma concentration Tmax), were observed 4398.1±7.90μgh/mL, 145.45±2.25μg/L, 45.74±0.25h, 72±0.50h, respectively of HAC NPs and 119.92±1.78μgh/mL, 46.38±3.42μg/L, 1.2±0.25h, 0.5±0.02h were observed in plain 5-FU solution.",Hyaluronic acid embedded cellulose acetate phthlate core/shell nanoparticulate carrier of 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26955748/),h,0.5,109786,DB08818,Hyaluronan
,32122838,total drug loading rate,The results showed a total drug loading rate of 8.76±0.95% for the optimized HA-OUR-NLC; total encapsulation efficiency was 45.67±1.14%; particle size was 165.15±3.84%; polydispersity index was 0.227±0.01; zeta potential was -22.87±0.97 mV.,Hyaluronic acid-coated nanostructured lipid carriers for loading multiple traditional Chinese medicine components for liver cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32122838/),%,8.76,111014,DB08818,Hyaluronan
,32122838,total encapsulation efficiency,The results showed a total drug loading rate of 8.76±0.95% for the optimized HA-OUR-NLC; total encapsulation efficiency was 45.67±1.14%; particle size was 165.15±3.84%; polydispersity index was 0.227±0.01; zeta potential was -22.87±0.97 mV.,Hyaluronic acid-coated nanostructured lipid carriers for loading multiple traditional Chinese medicine components for liver cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32122838/),%,45.67,111015,DB08818,Hyaluronan
,32122838,polydispersity index,The results showed a total drug loading rate of 8.76±0.95% for the optimized HA-OUR-NLC; total encapsulation efficiency was 45.67±1.14%; particle size was 165.15±3.84%; polydispersity index was 0.227±0.01; zeta potential was -22.87±0.97 mV.,Hyaluronic acid-coated nanostructured lipid carriers for loading multiple traditional Chinese medicine components for liver cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32122838/),,0.227,111016,DB08818,Hyaluronan
,32122838,zeta potential,The results showed a total drug loading rate of 8.76±0.95% for the optimized HA-OUR-NLC; total encapsulation efficiency was 45.67±1.14%; particle size was 165.15±3.84%; polydispersity index was 0.227±0.01; zeta potential was -22.87±0.97 mV.,Hyaluronic acid-coated nanostructured lipid carriers for loading multiple traditional Chinese medicine components for liver cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32122838/),m,-,111017,DB08818,Hyaluronan
,32122838,zeta potential,The results showed a total drug loading rate of 8.76±0.95% for the optimized HA-OUR-NLC; total encapsulation efficiency was 45.67±1.14%; particle size was 165.15±3.84%; polydispersity index was 0.227±0.01; zeta potential was -22.87±0.97 mV.,Hyaluronic acid-coated nanostructured lipid carriers for loading multiple traditional Chinese medicine components for liver cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32122838/),m,22.87,111018,DB08818,Hyaluronan
,10742587,particle size,"The microspheres had a mean particle size of 19.91+/-1.57 microm (HA), 28.60+/-1.34 microm (HA/CH), 29.47+/-3.58 microm (CH).",Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10742587/),μm,19.91,113192,DB08818,Hyaluronan
,10742587,particle size,"The microspheres had a mean particle size of 19.91+/-1.57 microm (HA), 28.60+/-1.34 microm (HA/CH), 29.47+/-3.58 microm (CH).",Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10742587/),μm,28.60,113193,DB08818,Hyaluronan
,10742587,particle size,"The microspheres had a mean particle size of 19.91+/-1.57 microm (HA), 28.60+/-1.34 microm (HA/CH), 29.47+/-3.58 microm (CH).",Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10742587/),μm,29.47,113194,DB08818,Hyaluronan
>,30077147,encapsulation efficiency,Maximum encapsulation efficiency (>95%) was observed at 40 mg/mL of PGMC or TPGS.,Mitoxantrone-loaded chitosan/hyaluronate polyelectrolyte nanoparticles decorated with amphiphilic PEG derivates for long-circulating effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077147/),%,95,113677,DB08818,Hyaluronan
,31655131,absolute bioavailability,After SC administration cetuximab absolute bioavailability increased from 67 % to 80 % in the presence of rHuPH20.,Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,67,115438,DB08818,Hyaluronan
,31655131,absolute bioavailability,After SC administration cetuximab absolute bioavailability increased from 67 % to 80 % in the presence of rHuPH20.,Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,80,115439,DB08818,Hyaluronan
,31655131,absolute bioavailability,"In contrast, co-administration with rHuPH20 did not lead to increases in plasma exposure for trastuzumab after SC or ID administration, most likely reflecting the fact that the reported absolute bioavailability of trastuzumab (in the absence of rHuPH20) is high (∼77-99 %).",Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,∼77-99,115440,DB08818,Hyaluronan
,30243219,zeta potential,The average size of spherical NAC-HA-PTX micelles was 187 nm with a zeta potential of -25.38 mV.,N-acetylcysteine modified hyaluronic acid-paclitaxel conjugate for efficient oral chemotherapy through mucosal bioadhesion ability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243219/),m,25.38,119609,DB08818,Hyaluronan
,7340841,half-life,"After intravenous injection in the rabbit the label disappeared from the plasma with a half-life of 2.5--4.5 min, which corresponds to a normal hyaluronic acid clearance of approx.","Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340841/),min,2.5,121282,DB08818,Hyaluronan
,7340841,maximum clearance capacity,The maximum clearance capacity was estimated in these circumstances to be about 30 mg/day per kg body wt.,"Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340841/),[mg] / [d·kg],30,121283,DB08818,Hyaluronan
,19819665,T(max),"Concomitant SC administration of rHuPH20 enhanced the absorption rate of morphine compared with SC morphine with placebo, significantly reducing the mean T(max) from 13.8 to 9.2 minutes, a 33% decrease (P=0.026).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),min,13.8,123698,DB08818,Hyaluronan
,19819665,T(max),"Concomitant SC administration of rHuPH20 enhanced the absorption rate of morphine compared with SC morphine with placebo, significantly reducing the mean T(max) from 13.8 to 9.2 minutes, a 33% decrease (P=0.026).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),min,9.2,123699,DB08818,Hyaluronan
,19819665,maximum plasma concentration,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[nM] / [l],94.9,123700,DB08818,Hyaluronan
,19819665,maximum plasma concentration,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[nM] / [l],107.5,123701,DB08818,Hyaluronan
,19819665,area under the plasma concentration vs. time curve,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[min·μM] / [l],7.7,123702,DB08818,Hyaluronan
,19819665,area under the plasma concentration vs. time curve,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[min·μM] / [l],7.2,123703,DB08818,Hyaluronan
,30149648,half-life,"The pharmacokinetic profile of PCA in tear fluid was characterized by high concentrations immediately after application, followed by a rapid decrease, with half-life values of 17.16 and 22.27 min for solutions containing PCA alone and in combination with HA, respectively, when 100 µL of solutions were instilled.",Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30149648/),min,17.16,138129,DB08818,Hyaluronan
,30149648,half-life,"The pharmacokinetic profile of PCA in tear fluid was characterized by high concentrations immediately after application, followed by a rapid decrease, with half-life values of 17.16 and 22.27 min for solutions containing PCA alone and in combination with HA, respectively, when 100 µL of solutions were instilled.",Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30149648/),min,22.27,138130,DB08818,Hyaluronan
,31444661,globule size,The optimized formulation indicated globule size of 113 nm with 29 mm inhibition zone.,"Preparation, Optimization, and Evaluation of Hyaluronic Acid-Based Hydrogel Loaded with Miconazole Self-Nanoemulsion for the Treatment of Oral Thrush. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31444661/),,113,144892,DB08818,Hyaluronan
,32963641,tmax,Plasma concentrations of rHuPH20 increased during the 5-minute intravenous infusion (median tmax = 6 minutes from intravenous initiation) followed by a rapid plasma clearance (t1/2 ∼10 minutes from intravenous initiation).,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32963641/),min,6,147448,DB08818,Hyaluronan
,32963641,tmax,Plasma hyaluronan concentrations increased with dose and time (tmax range = 45‒120 minutes from intravenous initiation) and returned to baseline within 1 week of administration.,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32963641/),min,45‒120,147449,DB08818,Hyaluronan
,31387217,en,"From characterization and evaluation study PLGA microparticles showed smaller particle size with higher entrapment efficiency, approximately 1100.4 ± 257.7 nm and 77.9 ± 2.8%, respectively.",Pharmacokinetic Profile and Anti-Adhesive Effect of Oxaliplatin-PLGA Microparticle-Loaded Hydrogels in Rats for Colorectal Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31387217/),nm,1100,149466,DB08818,Hyaluronan
,31387217,AUC0-48h,"In HC21 hydrogels, AUC0-48h, Cmax, and Tmax were 16012.12 ± 188.75 ng·h/mL, 528.75 ± 144.50 ng/mL, and 1.5 h, respectively.",Pharmacokinetic Profile and Anti-Adhesive Effect of Oxaliplatin-PLGA Microparticle-Loaded Hydrogels in Rats for Colorectal Cancer Treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31387217/),[h·ng] / [ml],16012.12,149467,DB08818,Hyaluronan
,31387217,Cmax,"In HC21 hydrogels, AUC0-48h, Cmax, and Tmax were 16012.12 ± 188.75 ng·h/mL, 528.75 ± 144.50 ng/mL, and 1.5 h, respectively.",Pharmacokinetic Profile and Anti-Adhesive Effect of Oxaliplatin-PLGA Microparticle-Loaded Hydrogels in Rats for Colorectal Cancer Treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31387217/),[ng] / [ml],528.75,149468,DB08818,Hyaluronan
,31387217,Tmax,"In HC21 hydrogels, AUC0-48h, Cmax, and Tmax were 16012.12 ± 188.75 ng·h/mL, 528.75 ± 144.50 ng/mL, and 1.5 h, respectively.",Pharmacokinetic Profile and Anti-Adhesive Effect of Oxaliplatin-PLGA Microparticle-Loaded Hydrogels in Rats for Colorectal Cancer Treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31387217/),h,1.5,149469,DB08818,Hyaluronan
,30087553,drug loading amount,"The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively.",HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087553/),%,5.6,167418,DB08818,Hyaluronan
,30087553,encap,"The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively.",HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087553/),%,5.6,167419,DB08818,Hyaluronan
,30087553,encap,"The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively.",HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087553/),%,81.2,167420,DB08818,Hyaluronan
,2607093,half-life,"Plasma radioactivity decayed by first-order kinetics, with a half-life between 0.8 and 1.25 min.",Elimination and subsequent metabolism of circulating hyaluronic acid in the fetus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2607093/),min,0.8 and 1.25,168196,DB08818,Hyaluronan
,2607093,plasma turnover,Estimated plasma turnover was in the order of 10 micrograms/min per kg body weight.,Elimination and subsequent metabolism of circulating hyaluronic acid in the fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2607093/),[μg] / [kg·min],10,168197,DB08818,Hyaluronan
,22272720,terminal half-life,"The drug was distributed in liver,but not spleen, and was eliminated with a terminal half-life of 16 h.",Pharmacokinetic profile of Oncofid-S after intraperitoneal and intravenous administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22272720/),h,16,173701,DB08818,Hyaluronan
,27086168,zeta potential,"Scanning electron microscopy revealed hollow needle-shaped particle ultrastructure, with a zeta potential of -35.5mV determined by electrophoretic light scattering.",A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086168/),mv,35.5,174897,DB08818,Hyaluronan
,28717975,entrapment efficiency,An entrapment efficiency of 85% was achieved as ACV has enhanced affinity for the hydrophobic inner core of the complex.,Development of a Novel Polymeric Nanocomposite Complex for Drugs with Low Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28717975/),%,85,175034,DB08818,Hyaluronan
,17332932,half-lives,"For BIWI 1 and deconjugated BIWI 1, clearance values were low and distribution was limited resulting in half-lives of approximately 3-3.5 days and approximately 6-7 days, respectively, for single and repeated dosing after three weeks.","Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332932/),d,3-3.5,178722,DB08818,Hyaluronan
,17332932,half-lives,"For BIWI 1 and deconjugated BIWI 1, clearance values were low and distribution was limited resulting in half-lives of approximately 3-3.5 days and approximately 6-7 days, respectively, for single and repeated dosing after three weeks.","Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332932/),d,6-7,178723,DB08818,Hyaluronan
,20978165,t(1/2),"Pegylation improved serum half-life (t(1/2) = 10.3 hours), making it feasible to probe the effects of sustained HA depletion on tumor physiology.",Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20978165/),h,10.3,181491,DB08818,Hyaluronan
,2813260,apparent T 1/2,"At a normal plasma HA concentration (0.12 +/- 0.05 microgram/ml; range, 0.072-0.228 microgram/ml), the apparent T 1/2 of 3H-HA was 5.3 +/- 1.1 min (range, 3.3-6.5 min).",A pharmacokinetic model of intravenously administered hyaluronan in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813260/),min,5.3,192138,DB08818,Hyaluronan
,2813260,apparent T 1/2,"At higher plasma concentrations (range, 1.83-3.35 micrograms/ml), the apparent T 1/2 was considerably prolonged (range, 18.2-43.5 min).",A pharmacokinetic model of intravenously administered hyaluronan in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813260/),min,18.2-43.5,192139,DB08818,Hyaluronan
,2813260,"Michaelis-Menten constant, Km","The Michaelis-Menten constant, Km, was 0.12 +/- 0.04 microgram/ml, indicating that a deviation from linear kinetics will occur when the normal plasma concentration is exceeded.",A pharmacokinetic model of intravenously administered hyaluronan in sheep. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813260/),[μg] / [ml],0.12,192140,DB08818,Hyaluronan
,2813260,Vmax,The Vmax was 0.062 +/- 0.009 microgram/ml/min.,A pharmacokinetic model of intravenously administered hyaluronan in sheep. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813260/),[μg] / [min·ml],0.062,192141,DB08818,Hyaluronan
,8942594,apparent t1/2,"The dog exhibited ""flip-flop"" pharmacokinetics and absorption was biphasic after epidural administration of lidocaine solution (apparent t1/2 of the fast and slow absorption phases were 4 min and 131 min, respectively).",Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8942594/),min,4,193560,DB08818,Hyaluronan
,8942594,apparent t1/2,"The dog exhibited ""flip-flop"" pharmacokinetics and absorption was biphasic after epidural administration of lidocaine solution (apparent t1/2 of the fast and slow absorption phases were 4 min and 131 min, respectively).",Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8942594/),min,131,193561,DB08818,Hyaluronan
,8942594,apparent t1/2,"The L-HA formulation markedly altered the absorption kinetics such that a single, slow absorption phase was evident (apparent t1/2 of 56 min), although this rate was more rapid than the slow phase observed after lidocaine solution.",Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8942594/),min,56,193562,DB08818,Hyaluronan
,1506757,t1/2,"Intravenously-administered HA disappeared rapidly from the blood of rabbits and rats with a mean t1/2 of 5.3 and 3.7 min, respectively.","Absorption, distribution, metabolism, and excretion of bacteria-derived hyaluronic acid in rats and rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506757/),min,5.3,211862,DB08818,Hyaluronan
,1506757,t1/2,"Intravenously-administered HA disappeared rapidly from the blood of rabbits and rats with a mean t1/2 of 5.3 and 3.7 min, respectively.","Absorption, distribution, metabolism, and excretion of bacteria-derived hyaluronic acid in rats and rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506757/),min,3.7,211863,DB08818,Hyaluronan
,1506757,t1/2,The disposition of viscous 14C-HA administered into the anterior eye chamber of rabbits was slow and followed first-order kinetics with a t1/2 of 10.5h.,"Absorption, distribution, metabolism, and excretion of bacteria-derived hyaluronic acid in rats and rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506757/),h,10.5,211864,DB08818,Hyaluronan
,31956378,terminal half-life,"Plasma and knee cartilage were collected postadministration and the terminal half-life was similar in both matrices (about 5 days), for both 3H-HA and 14C-CS.",Intra-Articular Hyaluronic Acid and Chondroitin Sulfate: Pharmacokinetic Investigation in Osteoarthritic Rat Models. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956378/),d,5,216822,DB08818,Hyaluronan
,15059558,recovery rate,The average recovery rate of pilocarpine from aqueous humor was 98.2%.,[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),%,98.2,227393,DB08818,Hyaluronan
,15059558,minimum detectable concentration,The minimum detectable concentration was 0.025 micro g/ml.,[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),[μg] / [ml],0.025,227394,DB08818,Hyaluronan
,15059558,peak concentration,"The peak concentration and half-life of pilocarpine in aqueous humor were 4.46 micro g/ml at 10 min and 31.83 min, respectively, in the experimental group.",[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),[μg] / [ml],4.46,227395,DB08818,Hyaluronan
,15059558,peak concentration,"Whereas, the peak concentration and half-life of pilocarpine in aqueous humor were 2.25 micro g/ml at 20 min and 22.98 min, respectively, in the control group.",[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),[μg] / [ml],2.25,227396,DB08818,Hyaluronan
,24135268,CMC,"These copolymers could form nanoparticles with small size (<200 nm), an acceptable CMC (~7.9 mg/L), typical core/shell structure and superior stability in one week.","Biodegradable self-assembled nanoparticles of poly (D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135268/),[mg] / [l],7.9,228116,DB08818,Hyaluronan
,7828634,Km,"Km and Vmax was estimated to 0.34 +/- 0.13 microgram ml-1 and 3.48 +/- 0.97 microgram min-1 kg-1 b.w., respectively.",Kinetics of circulating hyaluronan in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828634/),[μg] / [ml],0.34,229718,DB08818,Hyaluronan
,7828634,Vmax,"Km and Vmax was estimated to 0.34 +/- 0.13 microgram ml-1 and 3.48 +/- 0.97 microgram min-1 kg-1 b.w., respectively.",Kinetics of circulating hyaluronan in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828634/),[μg] / [kg·min],3.48,229719,DB08818,Hyaluronan
,7828634,endogenous input,The endogenous input was calculated to be 24 +/- 11 micrograms min-1 and was found to correlate to the age of the subjects (P < 0.05).,Kinetics of circulating hyaluronan in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828634/),[μg] / [min],24,229720,DB08818,Hyaluronan
,7828634,total amount of,"The total amount of HA excreted by the kidneys during the study period was 394 +/- 77 micrograms, which corresponded to approximately 1.7% of the total input of HA into the circulation during the experiment.",Kinetics of circulating hyaluronan in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828634/),μg,394,229721,DB08818,Hyaluronan
,23932961,total single run time,A total single run time was as short as 3.0min.,Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23932961/),min,3.0,232817,DB08818,Hyaluronan
,23932961,extraction recoveries,"The mean extraction recoveries of PTX and IS were 94.7% and 87.5%, respectively.",Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23932961/),%,94.7,232818,DB08818,Hyaluronan
,23932961,extraction recoveries,"The mean extraction recoveries of PTX and IS were 94.7% and 87.5%, respectively.",Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23932961/),%,87.5,232819,DB08818,Hyaluronan
,15665619,t(1/2),"The mean t(1/2) in plasma of BIWA 4 (ELISA( was 81 hours (range, 67-97(, whereas the mean radioactivity t(1/2) tended to be longer, at 105 hours (range, 90-114(.","Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665619/),h,81,233383,DB08818,Hyaluronan
,15665619,t(1/2),"The mean t(1/2) in plasma of BIWA 4 (ELISA( was 81 hours (range, 67-97(, whereas the mean radioactivity t(1/2) tended to be longer, at 105 hours (range, 90-114(.","Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665619/),h,105,233384,DB08818,Hyaluronan
,15665619,tumor uptake,"Mean tumor uptake was 2.96% ID/kg (range, 0.92-6.27(, with no apparent correlation with either tumor CD44v6 expression, tumor-cell cellularity, or tumor diameter.","Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665619/),[%·id] / [kg],2.96,233385,DB08818,Hyaluronan
,32084574,polydispersity index,"Loratadine nanosuspension displayed a particle size of 311 nm, a polydispersity index of 0.16, and zeta potential of -22.05 mV.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),,0.16,234418,DB08818,Hyaluronan
,32084574,zeta potential,"Loratadine nanosuspension displayed a particle size of 311 nm, a polydispersity index of 0.16, and zeta potential of -22.05 mV.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),m,22.05,234419,DB08818,Hyaluronan
,32084574,flux,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[μg] / [(cm)^2·h],1.49,234420,DB08818,Hyaluronan
,32084574,permeability coefficient,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[μg] / [(cm)^2·h],1.49,234421,DB08818,Hyaluronan
,32084574,flux,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[cm] / [h],0.017,234422,DB08818,Hyaluronan
,32084574,permeability coefficient,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[cm] / [h],0.017,234423,DB08818,Hyaluronan
,31553572,half-life,"Compared to free Fab (observed vitreal half-life of 2.8 days), HA-Fab conjugates cleared with observed half-lives of 7.6, 10.2, and 18.3 days for 40 kDa, 200 kDa, and 600 kDa HA conjugates, respectively.",Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31553572/),d,2.8,243060,DB08818,Hyaluronan
,31553572,observed half-lives,"Compared to free Fab (observed vitreal half-life of 2.8 days), HA-Fab conjugates cleared with observed half-lives of 7.6, 10.2, and 18.3 days for 40 kDa, 200 kDa, and 600 kDa HA conjugates, respectively.",Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31553572/),d,7.6,243061,DB08818,Hyaluronan
,31553572,observed half-lives,"Compared to free Fab (observed vitreal half-life of 2.8 days), HA-Fab conjugates cleared with observed half-lives of 7.6, 10.2, and 18.3 days for 40 kDa, 200 kDa, and 600 kDa HA conjugates, respectively.",Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31553572/),d,10.2,243062,DB08818,Hyaluronan
,31553572,observed half-lives,"Compared to free Fab (observed vitreal half-life of 2.8 days), HA-Fab conjugates cleared with observed half-lives of 7.6, 10.2, and 18.3 days for 40 kDa, 200 kDa, and 600 kDa HA conjugates, respectively.",Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31553572/),d,18.3,243063,DB08818,Hyaluronan
,16140028,PC20 metha,"Sixteen asthmatic patients with EIB were included in the study (mean (SD)) (age 24.5 (7.3) yr, FEV1 88.6 (11.3) %predicted, PC20 methacholine (g-mean (SD in DD)) 0.4 (1.5) mg/ml).",Inhaled hyaluronic acid against exercise-induced bronchoconstriction in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16140028/),[mg] / [ml],0.4,243315,DB08818,Hyaluronan
,16140028,AUC,"The maximum fall in FEV1 following exercise challenge was not significantly different between HA versus placebo (median HA 22.50%, placebo 27.20%, P=0.379), as was the AUC (median HA 379.3 min*%fall, placebo 498.9 min*%fall, P=0.501).",Inhaled hyaluronic acid against exercise-induced bronchoconstriction in asthma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16140028/),%fall·min,379.3,243316,DB08818,Hyaluronan
,16140028,AUC,"The maximum fall in FEV1 following exercise challenge was not significantly different between HA versus placebo (median HA 22.50%, placebo 27.20%, P=0.379), as was the AUC (median HA 379.3 min*%fall, placebo 498.9 min*%fall, P=0.501).",Inhaled hyaluronic acid against exercise-induced bronchoconstriction in asthma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16140028/),%fall·min,498.9,243317,DB08818,Hyaluronan
,25381135,Half-life,"Half-life of XG in the joint cavity was 35.9 h, with clearance obeying first-order kinetics.",Viscosupplementation of synovial fluid with xanthan gum for treatment of osteoarthritis and its clearance kinetics in the rabbit knee joint. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25381135/),h,35.9,244648,DB08818,Hyaluronan
,28176896,loading content,"The PTX loading content was 3 mg/mL, and encapsulation efficiency (EE) was close to 100%.",Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176896/),[mg] / [ml],3,254556,DB08818,Hyaluronan
,28176896,encapsulation efficiency (EE),"The PTX loading content was 3 mg/mL, and encapsulation efficiency (EE) was close to 100%.",Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176896/),%,100,254557,DB08818,Hyaluronan
,15460071,terminal half-life,"After i.v. sodium hyaluronate administration (37.8 mg in toto), the terminal half-life was very short (43+/-29 mins) and after a delay of 3 h, the plasma concentration returned to control values.","Hyaluronan in horses: physiological production rate, plasma and synovial fluid concentrations in control conditions and following sodium hyaluronate administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15460071/),min,43,256404,DB08818,Hyaluronan
,15460071,production rate,"The endogenous HA production rate was 33-164 mg in toto per day, i.e. 1-4 times the recommended i.v. daily dose.","Hyaluronan in horses: physiological production rate, plasma and synovial fluid concentrations in control conditions and following sodium hyaluronate administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15460071/),mg,33-164,256405,DB08818,Hyaluronan
,24567264,serum half-life,PEGylation of CD44-3MUT prolonged its in vivo serum half-life about 70-fold from 0.03 to 1.8 hours.,"Purification, characterization and plasma half-life of PEGylated soluble recombinant non-HA-binding CD44. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24567264/),h,0.03,256624,DB08818,Hyaluronan
,24567264,serum half-life,PEGylation of CD44-3MUT prolonged its in vivo serum half-life about 70-fold from 0.03 to 1.8 hours.,"Purification, characterization and plasma half-life of PEGylated soluble recombinant non-HA-binding CD44. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24567264/),h,1.8,256625,DB08818,Hyaluronan
,31096017,zeta potential,"HA-pSL with an HA density of 179 μg/μmol had a larger size (152.3 vs 136.3 nm), and higher zeta potential (-46.8 vs -10.5 mV) than pSL.",Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096017/),mv,-,258054,DB08818,Hyaluronan
,31096017,zeta potential,"HA-pSL with an HA density of 179 μg/μmol had a larger size (152.3 vs 136.3 nm), and higher zeta potential (-46.8 vs -10.5 mV) than pSL.",Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096017/),mv,46.8,258055,DB08818,Hyaluronan
,31096017,zeta potential,"HA-pSL with an HA density of 179 μg/μmol had a larger size (152.3 vs 136.3 nm), and higher zeta potential (-46.8 vs -10.5 mV) than pSL.",Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096017/),mv,10.5,258056,DB08818,Hyaluronan
,19647176,T(1/2)alpha,Biokinetic studies showed a rapid blood clearance (T(1/2)alpha=21 min).,Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19647176/),min,21,259569,DB08818,Hyaluronan
,19647176,MTD,The liver MTD in mice was approximately 40 Gy after 7.4 MBq of (188)Re-HA injection.,Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19647176/),gy,40,259570,DB08818,Hyaluronan
,27155765,half-life,The 75 kD HA-Lys-Pt (75HA-Lys-Pt) sustained release of platinum with a 69 h half-life in phosphate buffered saline without substantial burst release.,"Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27155765/),h,69,261227,DB08818,Hyaluronan
,30940497,dose recovery percent,"The aerodynamic properties included fine particle fraction ranging between 24 and 30%, dose recovery percent of 68-8 5%, and average mass median aerodynamic diameter of 4.6-4.8 μm.",Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940497/),%,68-8 5,265754,DB08818,Hyaluronan
,30940497,mass median aerodynamic diameter,"The aerodynamic properties included fine particle fraction ranging between 24 and 30%, dose recovery percent of 68-8 5%, and average mass median aerodynamic diameter of 4.6-4.8 μm.",Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940497/),μm,4.6-4.8,265755,DB08818,Hyaluronan
>,28131945,ion diffusivity,"The in vivo pharmacokinetic study in rabbit tear fluid showed sustained HA release up to 15days, by fabricating implant (80μgHA loading) with 78.4μm thickness (total thickness of lens=100μm) using 0.925% of cross linker, with effective ion diffusivity>1.5×10-6mm2/min.",Design and optimization of a novel implantation technology in contact lenses for the treatment of dry eye syndrome: In vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28131945/),[mm2] / [min],1.5×10-6,267973,DB08818,Hyaluronan
,7837049,bioavailability,"In anaesthetized experiments, there were no significant changes in the bioavailability of insulin after addition of hyaluronate (0.84 +/- 0.11 vs 0.87 +/- 0.05%).",Effect of addition of hyaluronic acid to highly concentrated insulin on absorption from the conjunctiva in conscious diabetic dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837049/),%,0.84,269478,DB08818,Hyaluronan
,7837049,bioavailability,"In anaesthetized experiments, there were no significant changes in the bioavailability of insulin after addition of hyaluronate (0.84 +/- 0.11 vs 0.87 +/- 0.05%).",Effect of addition of hyaluronic acid to highly concentrated insulin on absorption from the conjunctiva in conscious diabetic dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837049/),%,0.87,269479,DB08818,Hyaluronan
,7837049,area under the curve of plasma insulin concentration,"In the conscious state, with addition of hyaluronic acid, the area under the curve of plasma insulin concentration was significantly increased (1842 +/- 383 vs 75 +/- 24 m units min L-1, P < 0.01).",Effect of addition of hyaluronic acid to highly concentrated insulin on absorption from the conjunctiva in conscious diabetic dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837049/),[m·min·units] / [l],1842,269480,DB08818,Hyaluronan
,7837049,area under the curve of plasma insulin concentration,"In the conscious state, with addition of hyaluronic acid, the area under the curve of plasma insulin concentration was significantly increased (1842 +/- 383 vs 75 +/- 24 m units min L-1, P < 0.01).",Effect of addition of hyaluronic acid to highly concentrated insulin on absorption from the conjunctiva in conscious diabetic dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837049/),[m·min·units] / [l],75,269481,DB08818,Hyaluronan
,7837049,bioavailability of,"The bioavailability of insulin absorption was significantly increased after addition of hyaluronate (0.68 +/- 0.14 vs 0.03 +/- 0.01%, P < 0.01).",Effect of addition of hyaluronic acid to highly concentrated insulin on absorption from the conjunctiva in conscious diabetic dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837049/),%,0.68,269482,DB08818,Hyaluronan
,7837049,bioavailability of,"The bioavailability of insulin absorption was significantly increased after addition of hyaluronate (0.68 +/- 0.14 vs 0.03 +/- 0.01%, P < 0.01).",Effect of addition of hyaluronic acid to highly concentrated insulin on absorption from the conjunctiva in conscious diabetic dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837049/),%,0.03,269483,DB08818,Hyaluronan
,29789008,maximum concentration,"In the pharmacokinetic study, the DF concentration in the synovium after SI-613 administration reached its maximum concentration of 311.6 ng/g on day 1, and gradually declined to 10 ng/g by day 28.","Pharmacological effects of N-[2-[[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]ethyl]hyaluronamide (diclofenac Etalhyaluronate, SI-613), a novel sodium hyaluronate derivative chemically linked with diclofenac. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29789008/),[ng] / [g],311.6,274108,DB08818,Hyaluronan
